Showing results (391-400 of 775) with videos related to
Sort By:
Pageof 78
Expert Opinion on Drug Metabolism & Toxicology|July 16, 2008
An updated review of acitretin--a systemic retinoid for the treatment of psoriasisMei-Lin Pang, Jenny E Murase, John KooCutis|June 8, 2023
Habit Reversal Therapy for Skin Picking DisorderRaagini Suresh Yedidi, John Koo, Jenny E MuraseJournal of Drugs in Dermatology : JDD|December 2, 2025
FDA Boxed Warnings: Should Package Inserts Include Levels of Evidence?Andrea Leung, Tina Bhutani, Nicholas Brownstone, et al.Dermatologic Clinics|January 31, 2012
Quality-of-life instruments: evaluation of the impact of psoriasis on patientsMisha M Heller, Jillian W Wong, Tien V Nguyen, et al.Journal of the American Academy of Dermatology|October 21, 2017
Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis RegistryBruce Strober, Chitra Karki, Marc Mason, et al.The Journal of Dermatological Treatment|August 26, 2022
Impact of secukinumab on patient-reported outcomes in biologic-naive patients with psoriasis in a US real-world settingBruce Strober, Dhaval Patil, Robert R McLean, et al.Journal of the American Academy of Dermatology|March 29, 2003
Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areasAmy Krupnick Freeman, Gregory J Linowski, Christopher Brady, et al.Journal of the American Academy of Dermatology|July 21, 2015
Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasisAlan Menter, Diamant Thaçi, Kim A Papp, et al.Dermatologic Therapy|August 21, 2021
Three-year U.S. pharmacovigilance report of brodalumabMark Lebwohl, Craig Leonardi, April Armstrong, et al.Journal of the American Academy of Dermatology|November 4, 2004
Tacrolimus ointment is effective for facial and intertriginous psoriasisMark Lebwohl, Amy Krupnick Freeman, M Shane Chapman, et al.Pageof 78